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Abstract
 
Primary effusion lymphomas (PELs) associated with infection by the Kaposi’s sarcoma–associated
herpesvirus (KSHV/HHV-8) have constitutive nuclear factor (NF)–
 
 
 
B activity that is essential
for their survival, but the source of this activity is unknown. We report that viral FADD-like
interleukin-1-
 
 
 
–converting enzyme [FLICE/caspase 8]-inhibitory protein (FLIP) activates
NF-
 
 
 
B more potently than cellular FLIP in B cells and that it is largely responsible for NF-
 
 
 
B
activation in latently infected PEL cells. Elimination of vFLIP production in PEL cells by RNA
interference results in significantly decreased NF-
 
 
 
B activity, down-regulation of essential
NF-
 
 
 
B–regulated cellular prosurvival factors, induction of apoptosis, and enhanced sensitivity
to external apoptotic stimuli. vFLIP is the first virally encoded gene shown to be essential for
the survival of naturally infected tumor cells.
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Introduction
 
Activation of nuclear factor (NF)–
 
 
 
B is a mechanism used
by lymphomagenic viruses to prolong cellular survival and
induce proliferation. EBV and human T cell leukemia virus
1 (HTLV-1) encode viral (v) oncoproteins, mainly LMP1
and Tax, that subvert cellular signaling pathways to consti-
tutively activate NF-
 
 
 
B (1–4). Another lymphomagenic
virus, Kaposi’s sarcoma-associated herpesvirus (KSHV, also
called human herpesvirus 8 or HHV-8), infects B cells and
is present in B cell lymphoproliferative disorders, specifi-
cally primary effusion lymphomas (PELs; reference 5) and a
subset of cases of multicentric Castleman’s disease (6) and
associated plasmablastic lymphomas (7). Like other virus-
associated lymphomas, the transcription factor NF-
 
 
 
B is
constitutively activated in PEL cells, and is essential for
their survival (8). We postulated that expression of viral
genes was a primary source of constitutive activation of
NF-
 
 
 
B in PEL cells. Consistent with this has been our
previous finding that types of NF-
 
 
 
B complexes, although
varying in levels of intensity, are identical among different
KSHV-infected PEL cell lines, which suggests a common
source of activation.
Apoptotic cell death is a tightly regulated process that is
crucial for the defense against certain infectious diseases and
cancer. Interaction between immune effector cells as well
as some infected cells can lead to apoptosis by the exogenous
or death receptor pathway. Death receptors are a family of
transmembrane proteins that belong to the TNF family of
receptors (9). They all contain a cytoplasmic sequence
called death domain (DD) that couples each receptor to
caspases, inducing death signals that trigger apoptosis. Current
understanding suggests that binding of extracellular death
ligands to their receptors, such as the Fas ligand to Fas, results
in conformational changes of preformed receptor clusters
(10). This leads to recruitment of the bipartite molecule
Fas-associated (FA)DD, composed of an amino terminal
death effector domain (DED) and a carboxyl terminal DD.
FADD binds to Fas via homophilic DD–DD interactions
and recruits the upstream DED-containing procaspase 8
to the receptor by homophilic DED–DED interactions.
This forms the death-inducing signaling complex (DISC),
which autoactivates itself via proteolytic cleavage of caspase
8 and induces apoptosis by subsequent cleavage of down-
stream effector caspases.
 
Address correspondence to Ethel Cesarman, Dept. of Pathology,
Weill Medical College of Cornell University, 1300 York Ave., New
York, NY 10021. Phone: (212) 746-8838; Fax: (212) 746-4483;
email: ecesarm@med.cornell.edu
 
Abbreviations used in this paper:
 
 DD, death domain; DED, death effector
domain; DISC, death-inducing signaling complex; Doxy, doxycycline;
EMSA, electrophoretic mobility shift assay; FA, Fas-associated; FLIP,
FADD-like interleukin-1-
 
 
 
–converting enzyme [FLICE/caspase 8]-
inhibitory protein; HTLV-1, human T cell leukemia virus 1; IBL, immu-
noblastic lymphoma; IKK, I
 
 
 
B kinase; KSHV, Kaposi’s sarcoma–associated
herpesvirus; LANA, latency-associated nuclear antigen; NF, nuclear
factor; PARP, poly (ADP-ribose) polymerase; PEL, primary effusion
lymphoma; si, small interfering; vCYC, viral cyclin; vGPCR, viral G
protein–coupled receptor. 
KSHV vFLIP in Lymphoma Cell Survival
 
994
Apoptosis is tightly regulated and can be inhibited at the
receptor level (receptor endocytosis, soluble ligands, and
decoy receptors) during signal transduction and at the ef-
fector stage (caspase inhibitors such as CrmA, p35, IAPs,
BCL-2, etc.). The transcription factor NF-
 
 
 
B can inhibit
apoptosis by controlling the expression of some of these
antiapoptotic inhibitory proteins. A different and direct
mechanism of apoptosis inhibition is mediated by a group
of inhibitors of death receptor–induced apoptosis, called
FLIP (FADD-like interleukin-1-
 
 
 
–converting enzyme
[FLICE/caspase 8]-inhibitory protein; reference 11), but
also having received the names of FLAME-1, I-FLICE,
Casper, CASH, MRIT, CLARP, and Usurpin. FLIP pro-
teins contain two DED domains and were shown to inhibit
DED–DED interactions between FADD and procaspases 8
and 10. Two forms of cellular FLIP have been identified
and characterized, both of which can inhibit caspase 8 acti-
vation at the DISC. These are cFLIP
 
L
 
 (long form) and
cFLIP
 
S
 
 (short form), which correspond to splice variants.
cFLIP
 
S
 
 consists of two DEDs with a short cytoplasmic tail,
whereas cFLIP
 
L
 
 has an additional COOH-terminal cas-
pase domain and resembles procaspase 8 in its overall struc-
tural organization, but lacks proteolytic activity (12). Only
cFLIP
 
L
 
 has been found in human B cells by us (unpublished
data) and others (13) when using antibodies that recognize
both protein forms. Several viruses contain proteins with
two DED with slight homology to cFLIP. The first de-
scribed and most studied are MC159L from the Molluscum
Contagiousum virus, E8 from the Equine Herpes Virus 2,
and ORF71/K13 from KSHV (11, 14). Rhesus rhadinovi-
rus and herpesvirus saimiri also contain FLIP homologues,
but murine herpesvirus 68 does not. KSHV vFLIP has two
DED domains, and structurally most closely resembles
cFLIP
 
S
 
. When transfected into a murine B cell lymphoma
cell line, which was subsequently injected into immuno-
competent mice, it facilitated tumor growth, suggesting
that in confers cells with resistance to T cell–induced apop-
tosis (15). KSHV vFLIP has also been shown to be able to
activate the I
 
 
 
B kinase (IKK) complex and NF-
 
 
 
B in a va-
riety of ectopic overexpression systems, and to be present
in IKK complexes in PEL cells (14, 16, 17). In addition, a
recent paper by An et al. showed that vFLIP is responsible
for IL-6 expression in a PEL cell line, where suppression of
vFLIP resulted in a 100% reduction of AP-1 transcriptional
activity and 70% reduction of NF-
 
 
 
B activity, providing
the first direct evidence indicating that vFLIP is responsible
for a significant proportion of the constitutive NF-
 
 
 
B ac-
tivity observed in PEL cells (18).
In addition to KSHV vFLIP, three different viral trans-
membrane proteins have been shown to induce signaling
that leads to NF-
 
 
 
B activation in ectopic expression sys-
tems. These are K1 (19), viral G protein–coupled receptor
(vGPCR; reference 20), and K15 (21). We sought to con-
firm previous findings suggesting that vFLIP is responsible
for initiating and maintaining the signaling cascade respon-
sible for NF-
 
 
 
B in latently infected lymphoma cells, and to
exclude a possible contributory role for K1, vGPCR, and
K15 during latent infection. Our studies show that of these
genes, vFLIP is largely responsible for the constitutive NF-
 
 
 
B activity in PEL cells. In addition, we show that KSHV
vFLIP expression is essential for the survival of the infected
lymphoma cells.
 
Materials and Methods
 
Cloning and Expression Vectors. 
 
To clone KSHV vFLIP, viral
Cyclin (vCYC), and cellular FLIPs (long and short forms), cDNA
from the human PEL cell line BC3 was amplified using the
following specific primers: vFLIP, 5
 
 
 
-GGGATGGCCACT-
TACGGGGTT-3
 
 
 
 and 5
 
 
 
-GGTGTATGGCGATAGTGTTGG-
3
 
 
 
; vCYC, 5
 
 
 
-GGGATGGCAACTGCCAATAAC-3
 
 
 
 and 5
 
 
 
-
ATAGCTGTCCAGAATGCGCGG-3
 
 
 
; cFLIP
 
L
 
, 5
 
 
 
-GGGATG-
GCTGCTGAAGTCATCCAT-3
 
 
 
 and 5
 
 
 
-TATGTGTAGGA-
GAGGATAAGTTTC-3
 
 
 
; and cFLIP
 
S
 
, 5
 
 
 
-GGGATGGCTGC-
TGAAGTCATCCAT-3
 
 
 
 and 5
 
 
 
-ACATGGAACAATTTCCA-
AGGATTT-3
 
 
 
.
All the constructs were cloned into the eukaryotic expression
vector pcDNA3.1 (Invitrogen). Correct orientation and se-
quence integrity was confirmed by nucleotide sequencing. vFLIP
and cFLIP
 
L
 
 were also cloned in frame with a COOH-terminal
3X-FLAG in a CMV14 vector backbone (Sigma-Aldrich). Com-
parable expression of transfected plasmids was confirmed by RT-
PCR or immunoblot with an anti-FLAG monoclonal antibody.
vFLIP was also cloned into pTRUF2-Tet (22) by blunt end liga-
tion into the single NsiI site, and the resulting plasmid called
pTRUF2-tet/vFLIP.
 
Cell Lines and Culture Conditions. 
 
Cell lines used were as fol-
lows: PEL cell lines were BC1, BC2, BC5 (KSHV
 
 
 
/EBV
 
 
 
),
BC3, and BCBL-1 (KSHV
 
 
 
/EBV
 
 
 
). All of these were estab-
lished in our laboratory from lymphomatous effusions as de-
scribed previously (23, 24), except BCBL-1 (25) that was ob-
tained from the AIDS and Cancer Specimen Bank. Burkitt
lymphoma cell lines were Namalwa and BJAB, obtained from the
American Type Culture Collection. An EBV-positive immuno-
blastic lymphoma (IBL) cell line was derived in our labora-
tory from an HIV-positive patient. A lymphoblastoid cell line
(LCL9001) was obtained by infection of peripheral blood lym-
phocytes with EBV. Cells were grown in RPMI 1640 (GIBCO
BRL) supplemented with 10% heat-inactivated FBS (Atlanta Bi-
ologicals) and 50 mg/ml gentamicin (Sigma-Aldrich). The hu-
man embryonal kidney 293T cell line was grown in DMEM sup-
plemented with 10% FBS. Cells were cultured at 37
 
 
 
C in a
humidified atmosphere with 5% CO
 
2
 
. NF13 was established by
electroporation of Namalwa cells with 10 
 
 
 
g of pTRUF2-tet/
vFLIP. The cells were allowed to recover for 48 h in full culture
medium, and 1 mg/ml of Geneticin (Invitrogen) was added. Af-
ter 20 d under antibiotic selection, single cells approximated by
limiting dilution were placed on irradiated fibroblast feeder layers
(10
 
4
 
 to 2 
 
 
 
 10
 
4
 
 cells/well; 5,000 rad of cobalt 
 
 
 
-irradiation) in
96-well plates. After 2 wk, only wells with a single colony were
expanded. 76 clones were screened for tetracycline inducibility-
related protein expression by transfection with 10 
 
 
 
g of pTRE-
Luc (CLONTECH Laboratories, Inc.), containing a tetracycline
response element, and 
 
 
 
 2 
 
 
 
g/ml doxycycline (Doxy). Three
clonal populations were selected having low basal transcription
and up to 100-fold inducibility with the TRE-luciferase reporter
and an NF-
 
 
 
B luc reporter, as well as by RT-PCR and immu-
noblot analysis for vFLIP. One of these, NF-13, was chosen to
evaluate cellular gene expression. 
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Electrophoretic Mobility Shift Assays (EMSAs). 
 
Nuclear pro-
teins were evaluated for binding to a 
 
32
 
P-labeled oligonucleotide
probe corresponding to the Ig
 
 
 
 NF-binding sequence (a gift
from H.-C. Liou, Weill Medical College of Cornell University)
or Oct-1 (Promega) by EMSA. The methodology used was de-
scribed previously in detail (8).
 
Northern Blot Analysis. 
 
Total RNA was extracted with the
RNAZOL solution (GIBCO BRL) according to the manufac-
turer’s instructions. Poly(A)-selected RNA was isolated with the
PolyATract mRNA Isolation System (Promega). RNA samples
were treated with 2 U of RNase-free DNase I (Boehringer) be-
fore Northern blot analysis. 800 ng aliquots of poly(A)-selected
RNA were separated electrophoretically in 1.5% denaturing
formaldehyde agarose gel and blotted onto nylon filters (Du-
pont). After fixation, the blots were subjected to hybridization to
PCR-generated double-stranded DNA probes that had been 
 
32
 
P-
labeled by the random primer extension method. To evaluate
K15 expression, probes for the predominant (P) and minor (M)
forms were used. Washing of the filters and autoradiography was
performed according to standard methodology.
 
Transient Transfection and Luciferase Assays. 
 
BJAB and Namalwa
cells (5 
 
 
 
 10
 
6
 
) were transfected by electroporation (Gene Pulser
II; Bio-Rad Laboratories) at settings of 270 mV and 975 
 
 
 
F in
0.8-cm cuvettes (Invitrogen). The amount of DNA transfected
was equalized by addition of pcDNA3.1 control empty vector.
All the transfections were performed in the presence of pRSV-
RL vector (Promega), encoding renilla luciferase, to normalize
the results for the transfection efficiencies. After 48 h, lysates were
prepared using 1
 
 
 
 cell culture lysis reagent as specified by the
manufacturer (Promega). Luciferase assays were performed with a
luminometer (Dynex Tech). The NF-
 
 
 
B firefly luciferase re-
porter derived from a Ig
 
  
 
promoter was provided by H.-C. Liou.
Each experiment was independently performed a minimum of
three times, and within each experiment each transfection was
performed in triplicate.
Transient transfection of vCYC was performed using FuGene
6 transfection reagent (Roche). This method is highly efficient
for transfection of BC-3 cells, achieving delivery into up to 90%
of cells as determined by a control green fluorescent protein–
expressing plasmid. BC3 cells were plated in RPMI 1640 with-
out FBS at a density of 7.5 
 
  
 
10
 
5
 
 cells/ml (2 ml in a six-well
plate). 3 
 
 
 
l of FuGene 6 reagent were added in a small sterile
tube containing serum-free medium to a total of 100 
 
 
 
l. Subse-
quently, 2 
 
 
 
g of pcDNA3.1/vCYC were added to the prediluted
FuGene 6 and mixed gently. After 15 min of incubation, the
mixture was added to the cells. This method was also used to
transfect 3
 
 
 
 FLAG-tagged vFLIP and cFLIP
 
L
 
 into BC-3 cells.
Transient transfection experiments were performed in 293T
cells when the confluence of the cells was 30–50% using the Cal-
cium Phosphate Transcription System (GIBCO BRL).
 
RNA Interference. 
 
RNA duplexes were synthesized with 2-nt
(2
 
 
 
deoxy) uridine overhangs by Dharmacon Research. The target
region of vFLIP small interfering (si) RNA was 58 amino acids
downstream of the start codon. The siRNA target sequence to
vFLIP mRNA is 5
 
 
 
-AAGUGGUAUUGUUCCUCCUAA-3
 
 
 
. A
control scramble siRNA duplex was obtained from Dharmacon
(Scramble II Duplex). We performed the transfection of siRNA
duplex using Oligofectamine Reagent (Invitrogen) and assayed for
silencing 2 d after transfection. With this method, we achieved
delivery into 60–80% of the cells in each of the lymphoma cell
lines tested, as determined by transfection with a fluoresceinated
control siRNA and flow cytometric analysis (unpublished data).
For extended studies, the cells were transfected every 2 d, for a to-
tal of four transfections and an 8-d time course. Cells were plated
in 12-well plates at a density of 7.5 
 
 
 
 10
 
5
 
 cells/ml. For each well,
we used 1.68 
 
 
 
g siRNA duplex. We mixed 6 
 
 
 
l of 20 
 
 
 
M
siRNA duplex with 100 
 
 
 
l of OPTI-MEM (Invitrogen). In an-
other tube, 6 
 
 
 
l of Oligofectamine Reagent was mixed with 24
 
 
 
l of Opti-MEM, incubated for 10 min at room temperature.
These solutions were combined, mixed, and incubated for an-
other 25 min at room temperature. 76 
 
 
 
l of fresh Opti-MEM
were added to the tubes to obtain a final solution volume of 212
 
 
 
l, which was added to cultured cells. Each RNA interference ex-
periment was performed at least three times, and reporter assays
were performed in triplicate within each experiment.
 
Immunoblot Analysis. 
 
NF13 cells were plated at a density of
7.5 
 
 
 
 10
 
5
 
 cells/ml without Doxy (Sigma-Aldrich) or with 2 
 
 
 
g/
ml Doxy for 48 h. Namalwa cells were also evaluated with and
without 2 
 
 
 
g/ml Doxy as a control for drug effects. BC-3 cells
that were untransfected, mock-transfected, or transfected with
siRNA were collected 48 h after transfection. Lysates were pre-
pared in standard radioimmunoprecipitation assay buffer supple-
mented with 1 
 
 
 
g/ml each of aproptinin, leupeptinin, and pep-
statin; 0.5 mM phenylmethylsulfonyl fluoride; and 1 mM each
NAV04 and NaF (Sigma-Aldrich). Lysates were prepared from
three independent experiments and subsequently evaluated by
Western blotting. The proteins were quantitated by the Bradford
method, and 80 
 
 
 
g whole cell extract was loaded onto 7.5–
12.5% SDS-polyacrylamide gels. After electrophoresis, semi-dry
transfer to a polyvinylindene difluoride membrane (Millipore)
was performed. Blots were probed with primary Ab overnight
at 4
 
 
 
C. Horseradish peroxidase–conjugated secondary Ab was
added after washing and was detected by an enhanced chemilu-
minescence system (Amersham Biosciences).
The following primary Abs were used: anti-vFLIP (provided
by M. Collins, University College of London, London, UK; ref-
erence 26); anti-cFLIP, anti–cIAP-1, and cIAP-2 (Qbiogene);
anti–Bcl-X, anti–Bcl-2, and anti–IL-6 (Santa Cruz Biotechnol-
ogy, Inc.); anti-Caspase 3 (Upstate Biotechnology); anti-poly
(ADP-ribose) polymerase (PARP) (BD Biosciences); anti–latency-
associated nuclear antigen (LANA; ABI); anti-vCYC (Exalpha);
and anti–
 
 
 
-actin and anti-FLAG (Sigma-Aldrich).
 
Flow Cytometry Analysis.
 
Cells were placed in culture at a
density of 7.5 
 
 
 
 10
 
5
 
 cells/ml without anti-FAS Ab or with 800
ng/ml anti–human Fas ligand (B-R17; Upstate Biotechnology)
for 24 h. Annexin V analysis was performed as described by the
manufacturer (CLONTECH Laboratories, Inc.). In brief, 2 
 
 
 
10
 
5
 
 cells were washed once with 1
 
 
 
 binding buffer and resus-
pended in 200 
 
 
 
l of 1
 
 
 
 binding buffer. 5 
 
 
 
l FITC–Annexin V
was added, and the cells incubated for 15 min in the dark at room
temperature and analyzed by flow cytometry using a FACSCali-
bur™ (Becton Dickinson).
 
Results
 
The KSHV-encoded FLIP (vFLIP) Can Activate NF-
 
 
 
B.
We first sought to determine which of the KSHV-encoded
genes that can activate NF- B in ectopic expression sys-
tems is responsible for the constitutive NF- B activity seen
in PEL cells. We performed Northern blot analysis using
probes for vGPCR, K1, K15 (not depicted), and vFLIP
(Fig. 1), and compared the amount of transcripts in latently
infected PEL cells (BC1, BC2, and BC3) to the level of
NF- B as measured by EMSAs in these three PEL cell
lines. This analysis confirmed previous analyses (27, 28) in-KSHV vFLIP in Lymphoma Cell Survival 996
dicating that K1, vGPCR, and K15 are lytic genes that are
not significantly expressed by latently infected PEL cells,
whereas vFLIP is expressed at significant levels during la-
tency. In addition, we found that the transcript encoding
vFLIP is present in PEL cells at levels that correlate with
the degree of NF- B DNA-binding activity (Fig. 1). Be-
cause vFLIP is encoded in a bicistronic mRNA together
with vCYC, the levels of vCYC also parallel those of NF-
 B. However, in our hands, vCYC cannot activate NF- B
(see Fig. 5 B). The protein levels of vFLIP also paralleled
those of NF- B, as indicated by an immunoblot analysis
using a monoclonal antibody to vFLIP (Fig. 1). Although
this simple correlation is insufficient to draw firm conclu-
sions, it prompted us to further investigate the role of
vFLIP in PEL.
Activation of NF- B by vFLIP was evaluated in Na-
malwa cells by transient transfection assay, using a pcDNA3.1/
vFLIP construct and an NF- B firefly luciferase reporter
derived from the Ig  promoter. We chose Namalwa be-
cause this is a KSHV-negative B cell lymphoma line with
relatively low endogenous NF- B, and therefore, corre-
sponds to the same lineage as PEL, but does not contain
endogenous vFLIP. The luciferase activity was measured
48 h after transfection and it was found to be markedly in-
creased in the cells transfected with vFLIP as compared
with the control cells transfected with NF- B firefly lu-
ciferase reporter and empty vector (Fig. 2 A). This is the
first demonstration that vFLIP can indeed activate NF- B
in human B cells. Notably, vFLIP was a more potent acti-
vator of NF- B than saturating doses of TNF . Cellular
FLIP (the short and long isoforms, cFLIPS and cFLIPL)
were also evaluated for comparison. These were cloned
Figure 1. Correlation of NF-
 B activity and vFLIP expression
in PEL cell lines. (top) EMSA
using a NF- B–specific oligonu-
cleotide probe, demonstrating
constitutive activity in three PEL
cell lines. Competition with cold
NF- B and random oligonucle-
otides has confirmed the speci-
ficity of this binding (not de-
picted). The level of NF- B
activity was in the following order:
BC1 BC3 BC2. In all three
PEL lines, activity was higher
than in BJAB, a virus-negative
lymphoma cell line. (middle)
Northern blot analysis was per-
formed on polyA-selected RNA
extracted from the BC-1, -2, and
-3 cell lines, as well as from BC3
after induction of lytic replication
by treatment with tetradecanoyl
phorbol acetate (TPA) for 48 h. BJAB cells were used as negative control.
A probe that recognizes vFLIP and vCYC was used, and filters were re-
probed with  -actin to ensure even loading. (bottom) Immunoblot anal-
ysis with an antibody to vFLIP showed vFLIP protein in BC1, -2, and -3
cells, but not in KSHV-negative BJAB. Equal protein loading was found
in all four lanes with an antibody to  -actin.
Figure 2. Activation of NF-
 B by KSHV-encoded vFLIP.
(A) vFLIP induces NF- B tran-
scriptional activity in human lym-
phoma cells. Namalwa cells were
cotransfected by electroporation
with 5  g NF- B luciferase re-
porter plasmid, 0.5  g of control
renilla luciferase reporter (pRL-
CMV), and vFLIP expression
vector (vFLIP/pcDNA3.1) in the
indicated amounts, or empty
vector (pcDNA3.1). Total DNA
content was maintained at 25  g
with empty vector. In all experi-
ments, luciferase activities were
measured 48 h after transfection,
and firefly luciferase was normal-
ized to renilla luciferase (control
reporter) activity. Values shown
are averages (   SEM) of one
representative experiment out of
three in which each transfection
was performed in triplicate. As
an experimental control, cells
were transfected with reporter
constructs and treated with 100
ng/ml recombinant human TNF-  for 3 h (at which maximal activation was identified in previous time course experiments) before cell lysis (top). (B) Namalwa
cells were cotransfected with 5  g NF- B luciferase reporter plasmid, 0.5  g of control reporter (pRL-CMV), and 5 and 10  g of vFLIP, cFLIPL, or
cFLIPS expression vectors. (C) BC-3 cells were cotransfected with 5  g NF- B luciferase reporter plasmid, 0.5  g of control reporter (pRL-CMV), and
5 and 10  g of 3X-FLAG-tagged vFLIP and cFLIPL, or empty vector (P3X-FLAG-CMV14). NF- B activation was measured using a luciferase reporter
assay. No significant difference was found between FLAG-tagged and untagged proteins (not depicted). (D) Immunoblot analysis of extracts from trans-
fected BC-3 cells using an anti-FLAG monoclonal antibody is shown (top), indicating lower protein levels for vFLIP than cFLIPL in spite of higher NF- B–
inducing activity. Because the sizes of vFLIP and cFLIPL are very different, the bands in this figure were cut from a single gel to show only the specific band.Guasparri et al. 997
into the same vector (pcDNA3.1) and transiently cotrans-
fected in Namalwa cells with the NF- B luciferase re-
porter. vFLIP was a more potent activator of NF- B than
both forms of cFLIP (Fig. 2 B). When tested in 293T cells,
vFLIP was also a more potent activator of NF- B than
TNF , and the ability of vFLIP to induce NF- B was at
least 2-fold higher as compared with cFLIPL and 10-fold
higher than cFLIPS (unpublished data). To assess the levels
of the different FLIP proteins in the transfected cells using a
single antibody, and to determine whether the differences
in NF- B activity may be explained by variability protein
levels, we subcloned vFLIP and cFLIPL into a vector in
frame with a COOH-terminal 3X-FLAG. This also al-
lowed us to examine the ability of these proteins to activate
NF- B when transfected into BC-3 cells and to distinguish
them from the endogenous proteins. No significant differ-
ences in activity were found between FLAG-tagged and
untagged proteins (unpublished data). The vFLIP-FLAG
also showed higher activation of NF- B than cFLIPL-
FLAG in BC-3 (Fig. 2 C) and 293T cells (not depicted).
Proteins were extracted from these transfected cells, and
immunoblot analysis using an anti-FLAG antibody was
performed. We consistently found in BC-3 and 293T cells
that the levels of cFLIPL were approximately threefold
higher than those of vFLIP. This is probably due to higher
translation efficiency or stability of the cFLIPL protein be-
cause these differences were not seen by RT-PCR. These
results show that vFLIP has an intrinsically higher signaling
capacity than cFLIPL, and that the difference between viral
and cellular proteins is larger than that apparent in the re-
porter assays when protein levels are taken into account.
KSHV vFLIP Induces the Expression of Cellular Antiapop-
totic Genes. To better characterize the effect of KSHV
vFLIP in neoplastic B cells, this gene was cloned in
pTruf2-Tet, an inducible plasmid expression vector devel-
oped in our laboratory based on a combination of the tetra-
cycline-inducible system and adeno-associated virus (22)
and was stably transfected in Namalwa cells. Selected and
subcloned populations were tested for expression and in-
ducibility of vFLIP after treatment with Doxy. Three
clonal populations were selected, having low basal tran-
scription and up to 100-fold inducibility. Results from a
representative clone, designated NF13, are shown in Fig. 3.
NF- B activity was increased greater than two-fold in in-
duced cells as compared with the uninduced control cells.
Because NF- B is a transcription factor that controls a
number of cellular genes that are critical mediators of cell
survival and proliferation, we evaluated the effect of vFLIP
on cellular gene expression. We have identified a set of cel-
lular genes that are antiapoptotic NF- B targets in PEL
cells. These include cFLIPL (no cFLIP short was identified
in PEL cells), cIAP-1, and cIAP-2. We have also found
that BCL-XL and BCL-2 are not NF- B targets in PEL
cells (unpublished data). Expression of vFLIP induced by
Doxy in NF13 cells resulted in expression of cFLIPL, cIAP-1,
and cIAP-2, but no changes in BCL-XL (Fig. 3). No
changes in NF- B activity or expression of cFLIPL were
seen when the parental Namalwa cells were treated with
Doxy. These data suggest that virus-encoded vFLIP could
inhibit apoptosis by inducing expression of a specific set of
cellular NF- B–dependent antiapoptotic genes.
Inhibition of KSHV vFLIP by RNA Interference. We eval-
uated the role of vFLIP in PEL cells, which are naturally
infected with KSHV and presumably a target of trans-
formation by this virus, using RNA interference. We de-
veloped and tested a siRNA duplex that specifically targets
the KSHV vFLIP sequence, but not cFLIP or any other
known genomic sequence. This siRNA was transfected
into a PEL cell line (BC-3) and a significant inhibition
of vFLIP protein was obtained, as assessed by immuno-
blot analysis (Fig. 4 A). Although all experiments showed
marked silencing by immunoblot analysis, it appears to be
complete in some, partial in others, and seen by longer gel
exposure. This is probably due to a threshold of detection
by the antibody to vFLIP, where a small amount of resid-
ual vFLIP protein can no longer be detected. siRNA to
Figure 3. The KSHV-encoded FLIP induces NF-
 B and expression of NF- B–regulated cellular
genes in stably transfected lymphoma cells. (A) NF13
cells were transfected with 5  g NF- B luciferase
reporter plasmid and 0.5  g of control reporter
(pRL-CMV), divided, and cultured at 5   105 cells/
ml in the absence and presence of 2  g/ml Doxy. As
a control, the parental cell line, Namalwa, was similarly
treated with 2  g/ml Doxy. After 48 h, luciferase
activity was measured. Values shown are averages ( 
SEM) of one representative experiment out of three
in which each transfection was performed in tripli-
cate. (B) Proteins extracted from untreated and
Doxy-induced NF-13 cells were assessed for vFLIP
(to confirm induction), cFLIP, cIAP-1, cIAP-2, and
BCL-XL expression by Western blotting. BC-3 was
used as a positive control because it has constitutive
NF- B activity and expresses these proteins. The
Namalwa cells were also treated with Doxy to exclude
drug-related effects and evaluated for expression of
vFLIP and cFLIP. Actin reprobing was performed to assure even protein loading. Doxy induction and analysis of protein expression was con-
firmed in three independent experiments of which one representative is shown.KSHV vFLIP in Lymphoma Cell Survival 998
vFLIP was able to inhibit basal NF- B activity by  80%
in BC-3 cells, indicating that a substantial proportion of
the constitutive NF- B activity is being induced by vFLIP
(Fig. 4 B). Scramble siRNA used as a negative control did
not have a significant effect on NF- B activity and did not
affect the levels of vFLIP protein. This result confirms a
previously published work in which siRNA to vFLIP was
found to significantly inhibit NF- B reporter activity in
the BCBL-1 PEL cell line (18). We also confirmed that
siRNA to vFLIP inhibits transcription for an AP-1 re-
porter construct, as demonstrated previously (reference 18
and unpublished data).
To confirm the effect of vFLIP siRNA on NF- B activ-
ity, we performed EMSAs. We evaluated BC-1 and BC-3
cells transfected with siRNA to vFLIP, using mock-trans-
fected cells and cells transfected with scramble siRNA as
controls. Nuclear extracts were made 48 h after transfection
and evaluated for binding to a radiolabeled probe containing
an NF- B binding sequence. Silencing of vFLIP resulted in
a marked decrease of NF- B DNA binding activity (Fig. 4
C). In contrast, no significant changes were seen in the level
of proteins binding to an oligonucleotide containing an oc-
tamer binding motif, indicating that not all transcription fac-
tors are affected by vFLIP down-regulation.
Figure 4. Inhibition of endogenous
vFLIP by siRNA results in depletion of
constitutive NF- B activity in PEL cells.
(A) BC-3 cells were transfected with a
vFLIP siRNA (v) and scramble siRNA (s)
and compared with mock-transfected cells
(–). Protein extracts were prepared 48 h after
transfection. Actin reprobing was performed
to assure even protein loading. This experi-
ment has been performed at least 10 times,
and a representative immunoblot is shown.
(B) BC-3 cells were transfected with an
NF- B luciferase reporter plasmid and either
scramble siRNA as a control or siRNA for
vFLIP. Luciferase assays were performed
48 h after transfection. Values shown are
averages (   SEM) of one representative
experiment out of three in which each trans-
fection was performed in triplicate. (C) Elec-
trophoretic mobility shift assays using a radio-
labeled probe containing an NF- B–binding
site. BC-1 and BC-3 cells were transfected
with vFLIP siRNA (v) or scramble siRNA
(s) and compared with mock-transfected
cells (–). Cold competition using 50-fold
molar excess of an unlabeled NF- B oligo-
nucleotide (c) demonstrated the specificity of the protein–DNA-binding complexes. Nuclear extracts were prepared 48 h after transfection. In the lane
labeled H2O, water was used instead of nuclear extract. Binding to a radiolabeled oligonucleotide containing an octamer (Oct) motif was similarly examined
as a control for specificity and for nuclear protein amount (bottom), where cold competition (c) was performed with nuclear extracts from mock-
transfected cells and excess unlabeled oligonucleotide containing an octamer motif. This experiment was performed three times with similar results.
Figure 5. siRNA to vFLIP inhibits
vCYC, but this protein can be reconstituted
and its expression does not affect NF- B
activity. (A) BC-3 cells were transfected
with a vFLIP siRNA (v) and scramble
siRNA (s) with or without 2  g of a viral
cyclin (vCYC) expression vector at days 0, 2,
4, and 6, and compared to mock-transfected
cells (–). Protein extracts were prepared at
day 8. This experiment was performed three
times, and a representative immunoblot is
shown. (B) 293T cells were transfected with
5  g of NF- B luciferase reporter plasmid
in addition to 5  g of vFLIP/pcDNA3.1,
vCYC/pcDNA3.1, both, or vector alone.
Luciferase activities were measured 48 h
after transfection and firefly luciferase was
normalized to renilla luciferase (control re-
porter) activity. Values shown are averages
(  SEM) of one representative experiment
out of three in which each transfection was
performed in triplicate.Guasparri et al. 999
vFLIP is encoded in a bicistronic transcript also encod-
ing for vCYC. In addition, vFLIP is also present in a tricis-
tronic transcript encoding the LANA and also containing
downstream vCYC and vFLIP sequences. Therefore, it
was important to determine whether protein production
of LANA and/or vCYC is affected by the siRNA to
vFLIP. Our results indicate that LANA is unaffected by
siRNA to vFLIP. The reason for this protection is unclear;
LANA remains unchanged even after 8 d of siRNA treat-
ment, so it is unlikely to be due to a longer half life of the
protein. In contrast, expression of vCYC is dramatically
reduced (Fig. 5 A). To overcome the down-regulation of
vCYC, and to be able to dissociate the effects resulting
from loss of vFLIP from those due to vCYC inhibition,
we transfected vCYC as a monocistronic transcript and
expressed it independently of vFLIP in BC-3 cells. We
were able to achieve continuous expression of vCYC at
levels comparable to those of untreated BC-3 cells (Fig. 5
A). The functional effects of treatment with siRNA to
vFLIP described in the next paragraphs were also seen in
vCYC-transfected BC-3 cells, where vCYC protein levels
were maintained in the presence of siRNA to vFLIP, and
thus can be attributed to vFLIP down-regulation. In addi-
tion, transfection of vCYC did not induce NF- B, and
did not affect the NF- B activity induced by vFLIP (Fig. 5
B); thus, we did not find vCYC to be a contributing factor
to NF- B activation.
We assumed that a single transfection of siRNA into
PEL cells would lead to incomplete and transient delivery,
so we modified this approach by transfecting BC-3 cells
every 2 d with siRNA, thus achieving sufficient and pro-
longed inhibition of vFLIP in PEL cells. Proteins were ex-
tracted at various time points during the course of this ex-
periment, and the effect of vFLIP reduction on selected
cellular proteins was evaluated. siRNA to vFLIP decreased
the expression of the three NF- B–dependent cellular an-
tiapoptotic proteins examined, cFLIP, cIAP-1, and cIAP-2
(Fig. 6), although down-regulation of cIAP-1 was not im-
mediate, perhaps due to a long half life of this protein. Re-
constitution of vCYC did not affect this down-regula-
tion of cellular proteins, as shown for cFLIPL in Fig. 5
A. siRNA to vFLIP also decreased expression of cellular
IL-6, another NF- B–dependent factor, consistent with
recently published findings (18). siRNA to vFLIP did not
affect the levels of cellular BCL-2 and BCL-XL proteins,
which are not dependent on NF- B in PEL cells (unpub-
lished data), indicative of pathway specificity. These results
show that vFLIP is largely responsible for sustaining the
expression of cellular NF- B–dependent antiapoptotic genes
in PEL cells.
Figure 6. Inhibition of endogenous vFLIP by siRNA results in down-
regulation of NF- B–dependent proteins in PEL cells. BC-3 cell lines
were transfected with a vFLIP siRNA (v), scramble siRNA (s), or mock-
transfected (–) at days 0, 2, 4, and 6, and protein extracts were prepared at
the indicated time points. Western blot analysis was performed on these
extracts using antibodies to the indicated proteins. Actin reprobing was
performed to confirm even protein loading. Similar results were obtained
in three independent experiments.
Figure 7. Inhibition of endogenous vFLIP by siRNA results in apoptosis of PEL cells. (A) BC-3 cells were transfected with a vFLIP siRNA (v), scramble
siRNA (s), or mock-transfected (–) at days 0, 2, 4, and 6, with or without vCYC, and assessment of apoptosis was performed by annexin V staining at the
indicated time points. BC-3 cells were also evaluated for annexin V positivity at day 8 after being transfected once at day 0 (*) and twice at days 0 and 4
(**). Bars represent the average number of Annexin V positive cells (  SEM) of one representative experiment out of three in which each transfection
and analysis was performed in triplicate. Inset shows a representative flow cytometric histogram plot at day 8 for annexin V analysis of untreated BC-3
cells (dashed line), cells transfected with scrambled siRNA as a negative control (solid line), and cells treated with siRNA to vFLIP (gray line and filled
area). (B) Induction of apoptosis was confirmed by cleavage of caspase 3 and a caspase substrate, PARP, by Western blot analysis. Actin reprobing was
performed to confirm even protein loading. Three independent experiments were performed, and a representative Western blot is shown.KSHV vFLIP in Lymphoma Cell Survival 1000
Elimination of KSHV vFLIP Leads to Apoptosis of PEL
Cells. If NF- B activity is essential for the survival of PEL
cells, and vFLIP is responsible for this activity in latently in-
fected cells, elimination of vFLIP should lead to apoptosis.
However, it has never been shown that elimination of a
single viral gene results in apoptosis of infected lymphoma
cells. To test this, we have measured apoptosis by flow cy-
tometry for annexin V after inhibition of vFLIP by RNA
interference. Initially, we evaluated BC-3 cells transfected
with siRNA for apoptosis up to 48 h after transfection. Be-
cause no significant cell death was seen, vFLIP BC-3 cells
were transfected every 2 d (days 0, 2, 4, and 6), and an-
nexin V was evaluated at 2-d intervals (days 2, 4, 6, and 8,
before the next transfection), for a total of four transfec-
tions and an 8-d time course. The number of apoptotic
cells increases over time when transfected with siRNA to
vFLIP, and by day 8, a significant proportion of cells
( 80%) express surface annexin V. In contrast, cells simi-
larly transfected with nonspecific (scramble) siRNA and
mock-transfected cells remain largely viable (Fig. 7 A, 18
and 13% apoptotic cells). Reconstitution of BC-3 cells
with vCYC did not protect cells from apoptosis, indicating
that apoptosis results from vFLIP and not vCYC suppres-
sion. siRNA to vFLIP also resulted in partial cleavage of
caspase 3 and PARP, confirming induction of apoptosis
(Fig. 7 B). Because the possibility remained that multiple
transfections were inducing stress and sensitizing the cell to
apoptosis in the context of NF- B inhibition, we deter-
mined whether apoptosis would also occur in cells that had
only been transfected once (at day 0), or twice (at days 0
and 4). A similar proportion of cells underwent apoptosis as
in cells transfected four times (Fig. 7 A), but in all experi-
ments it took 6–8 d for this process to be obvious.
To exclude the possibility that the vFLIP siRNA induces
apoptosis through toxicity or other nonspecific mechanisms
mimicking those seen upon inhibition of NF- B, we
tested additional cell lines. siRNA was transfected every 2 d
for 8 d into four additional PEL cell lines, containing
KSHV and expressing vFLIP (BC-1, BCBL-1, BC-2, and
BC-5), and into four cell lines lacking KSHV, which in-
cluded two Burkitt lymphoma cell lines with low constitu-
tive NF- B activity (BJAB and Namalwa), as well as one
EBV-positive immunoblastic lymphoma cell line estab-
lished in our laboratory (IBL) and one lymphoblastoid cell
line (LCL9001), both with high constitutive NF- B activ-
ity. The results shown in Fig. 8 clearly demonstrate that
transfection of siRNA to vFLIP only leads to apoptosis of
the PEL cell lines, whereas the cell lines lacking endoge-
nous vFLIP are not significantly affected by this treatment.
cFLIP has been shown to inhibit apoptosis by virtue of
containing two DEDs, and preventing signaling from death
receptors to the upstream caspases (29, 30). vFLIP has also
been shown to inhibit Fas-mediated apoptosis and caspase
activation when transfected into a cell line that is sensitive
to death induction by this pathway (15). We evaluated
whether vFLIP contributes to resistance to Fas-mediated
apoptosis in PEL cells. We chose the sixth day time point
that provides suboptimal apoptosis by vFLIP inhibition
alone. We found that BC-3 cells are largely resistant to
Fas-mediated apoptosis, but when treated with siRNA to
vFLIP, there was a further increase in annexin V positivity
when Fas was engaged by agonistic antibodies (Fig. 9). This
increase was statistically significant (P   0.001). Therefore,
reduction of vFLIP not only leads to spontaneous apoptosis
but it sensitizes PEL to extrinsic apoptotic stimuli.
Figure 8. Only KSHV-positive PEL cell lines are
sensitive to vFLIP siRNA. The indicated cell lines
were transfected with a vFLIP siRNA (v), scramble
siRNA (s), or mock-transfected (–) at days 0, 2, 4, and
6, and flow cytometry using antibodies to annexin V
was performed at day 8. Bars represent the average
number of annexin V positive cells (  SEM) of an
experiment in which each transfection and analysis
was performed in triplicate. Efficiency of transfection
as documented by flow cytometry analysis after trans-
fection with a fluoresceinated siRNA to luciferase, was
comparable in all cell lines (not depicted). KSHV-
positive PEL cell lines (BC-1, BCBL-1, BC-2, and
BC-5) and KSHV-negative B cell lymphoma (BJAB,
Namalwa, and IBL) or lymphoblastoid cell lines
(LCLs) were evaluated.
Figure 9. Inhibition of vFLIP in BC-3 cells sensitizes them to FAS-
mediated apoptosis. BC-3 cells were transfected with a vFLIP siRNA (v)
or scramble siRNA (s) at days 0, 2, and 4, and flow cytometry using anti-
bodies to annexin V was performed at day 6. An agonistic antibody to Fas
was added as indicated 24 h before flow cytometry at a concentration of
800 ng/ml. Bars represent the average number of annexin V positive cells
(  SEM) of a representative experiment out of three, in which each trans-
fection and analysis was performed in triplicate. A Student’s t test showed
that the difference between the untreated and anti-FAS–treated cells in
conjunction with vFLIP siRNA was statistically significant (P   0.001).Guasparri et al. 1001
Discussion
Classic approaches to determine which proteins of onco-
genic viruses are involved in transformation cannot be used
to characterize KSHV. Although this virus is associated
with specific lymphoma subtypes (suggesting a role in their
pathogenesis), it is clearly not sufficient for their develop-
ment and additional cofactors are necessary. One of these is
probably EBV because a large proportion of PEL cells are
coinfected by both viruses, but other cofactors are still un-
known. A puzzling observation has been that in spite of the
fact that KSHV encodes several genes that are transforming
in vitro and/or are homologous to cellular oncogenes, in
vitro infection of B cells does not transform them (31).
This clearly distinguishes KSHV from EBV and may ex-
plain why KSHV-associated lymphomas are much less
common than those associated with EBV infection. Never-
theless, once a lymphoma develops, when both KSHV and
EBV are present, KSHV expresses a set of latent genes,
whereas EBV latent gene expression is fairly restricted (32).
In addition, alterations in common oncogenes and tumor
suppressor genes are rare, in spite of multiple cytogenetic
abnormalities (33, 34). These observations suggest that
KSHV may be a sustaining force in PEL, and the results
presented here support this notion.
We propose a model, illustrated in Fig. 10, whereby
vFLIP may act by two mechanisms: (a) by preventing acti-
vation of the DISC complex, and (b) by activating the NF-
 B signaling pathway, therefore inducing survival signals.
The potential for vFLIP to directly inhibit DISC function
is mainly suggested by homology to cFLIP long and short
forms, which have been clearly shown to affect cleavage
and/or release of caspase 8 (29, 30). However, there are
minimal data to support a direct role of vFLIP in the DISC;
a single paper indicates that vFLIP has the potential of play-
ing such a role because it can bind and inhibit cleavage of
procaspase 8 (35), but this interaction has only been shown
in transfected HeLa cells and never documented in PEL
cells. The second pathway, whereby vFLIP induces NF- B
and inhibits apoptosis by inducing expression of cellular
prosurvival factors is clearly demonstrated by our data. We
suggest that vFLIP forms an active signaling complex,
which we propose to call a life-inducing signaling complex
(LISC). At this time, it is unknown what elements are in
this complex in naturally KSHV-infected B cells, and
whether activity depends on the presence and/or activation
of TNF receptors. PEL cells do not express many of the
members of the TNF receptor family, and lack CD40,
which is expressed in most other B cell types and tumors.
However, they do express low levels or TNF-R2 and vari-
able levels of Fas (CD95; unpublished data) and TRAIL re-
ceptors (36). Published work based on ectopic overexpres-
sion systems and PEL cell lines suggests that vFLIP can
associate with the IKK complex, NIK, RIP, and TRAFs,
suggesting that these are components of the life-inducing
signaling complex (14, 16, 17). PEL cells express abundant
TRAF-2 protein, and variable levels of other TRAFs, but
no TRAF-1 (unpublished data). Binding of TRAF-2 to
the complex containing vFLIP probably leads to activation
of a kinase, perhaps RIP, MEKK1, or another as yet unde-
fined kinase that in turn leads to phosphorylation and acti-
vation of JNK (18) and the IKK complex. In turn, this
would lead to I B  phosphorylation and degradation, fol-
lowed by release of NF- B, that in PEL cells is formed
mainly by p65(Rel-A)/p50 heterodimers. Transcriptional
activation of cellular prosurvival proteins, including cIAP-1,
cIAP-2, and vFLIP, as well as cytokines such as IL-6, leads
to protection of virally infected cells from spontaneous
apoptosis. Of note, cFLIP feeds back into the same path-
way by interfering with the function of the DISC. Our
data indicating that vFLIP protects PEL cells from FAS-
mediated apoptosis can be explained by direct interference
of caspase activation by vFLIP, or by an indirect effect me-
diated by cFLIP and cIAP up-regulation.
In these studies, apoptosis was not immediate upon
down-regulation of vFLIP, and significant apoptosis was
only seen after 6 d of treatment with siRNA to vFLIP,
whether these were transfected once, twice, or four times.
A possible explanation is that some of the antiapoptotic
proteins that are controlled by NF- B have relatively long
half lives, and their decrease is gradual upon vFLIP silenc-
ing, as seen in the case of cIAP-1. It is likely that a thresh-
old exists in which a combination of antiapoptotic factors
are no longer sufficient to protect the cells from apoptotic
stimuli. For example, BCL-2 and BCL-XL are present
throughout the time course of our experiment, and they
may play a protective role until down-regulation of other
factors reaches a critically low level. In addition, we have
examined expression of a set of antiapoptotic proteins that
Figure 10. Model of vFLIP effect of cellular survival. We propose that
vFLIP may inhibit apoptosis via a direct mechanism, by disrupting activa-
tion of the DISC complex, and an indirect pathway by forming part of a
signaling complex that induces IKK phosphorylation (via an unknown
kinase or kinases), I B degradation, and NF- B activation. In turn, acti-
vation of NF- B up-regulates expression of genes that inhibit apoptosis,
which include cFLIP, cIAP1, and cIAP2. We do not know if TNF recep-
tors (active or inactive) are part of the vFLIP-containing complex and
whether this complex is located in membrane lipid rafts in proximity to
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we identified in previous analysis as being NF- B–depen-
dent (unpublished data), but it is likely that additional fac-
tors play a role in this process. It is also possible that silenc-
ing of vFLIP does not truly induce spontaneous apoptosis,
but rather sensitizes cells to extrinsic apoptotic stimuli, in-
cluding stress and low levels of basal death receptor signal-
ing. Therefore, it is very likely that down-regulation of
vFLIP will also sensitize cells to cyototoxic compounds and
greatly enhance their therapeutic effect.
Our data support the theory that vFLIP, out of all
KSHV-encoded genes, is the gene most functionally analo-
gous to that of EBV-encoded oncoproteins LMP-1 and
HTLV-I–encoded Tax. Although obvious functional dif-
ferences exist between these three proteins, they share ex-
pression during latency and the ability to activate NF- B.
Activation of NF- B has emerged as a method by which
EBV, HTLV-1, and KSHV protect the host cell from
apoptosis to ensure establishment of viral latency and stable
infection, with the unfortunate result of becoming a com-
mon pathway in viral lymphomagenesis.
Suppression of vFLIP induces apoptosis of PEL cells,
demonstrating that this single gene encoded by KSHV is
essential for the survival of infected lymphoma cells. This is
the first demonstration that elimination of a single viral
protein leads to the death of infected lymphoma cells. Our
findings identify vFLIP as a disease-specific therapeutic tar-
get for the treatment of PEL and perhaps other KSHV-
associated diseases.
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